What is already known
- Evogliptin is a DPP-4 inhibitor used as treatment for type 2 diabetes
mellitus.
- Many guidelines recommend the use of combination therapy as treatment
for type 2 diabetes mellitus.
- There are no pharmacokinetic nor pharmacodynamic data of
co-administration of evogliptin and pioglitazone although many DPP-4
inhibitors showed no pharmacokinetic interactions with pioglitazone.